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Abstract 
(1) Aims/hypothesis. Glucagon-like peptide 1 (GLP1) receptors are expressed by pancreatic beta cells 
and promote insulin secretion. GLP1 receptor agonists have neural effects and are therapeutically 
promising against mild cognitive impairment and Alzheimer’s disease. Our recent results showed that 
insulin is released by neurogliaform neurons in the cerebral cortex, but the expression of GLP1 
receptors on insulin producing neocortical neurons has not been tested. In this study, we aim to 
determine whether GLP1 receptors are present in insulin containing neurons. 
(2) Methods. We harvested the cytoplasm of electrophysiologically and anatomically identified 
neurogliaform interneurons during patch clamp recordings performed in slices of rat neocortex. Using 
single cell digital PCR, we determined copy numbers of the Glp1r mRNAs and other key genes in 
neurogliaform cells harvested in conditions corresponding to hypo- (0.5 mM) and hyperglycemia (10 
mM). In addition, we performed whole cell patch clamp recordings on neurogliaform cells to test the 
effect of GLP1 receptor agonists for functional validation of single cell digital PCR results.  
(3) Results. Single cell digital PCR revealed GLP1 receptor expression in neurogliaform cells and 
showed that copy numbers of mRNAs of the Glp1r gene in hyperglycemia exceeded that of 
hypoglycemic copy numbers by 9.6 times (P<0.008). Moreover, single cell digital PCR confirmed co-
expression of Glp1r and Ins2 mRNAs in neurogliaform cells. Functional expression of GLP1 receptors 
was confirmed with whole cell patch clamp electrophysiology showing reversible effect of GLP1 on 
neurogliaform cells. In addition, single cell digital PCR of neurogliaform cells revealed expression of 
transcription factors (Pdx, Isl1, Mafb) important in beta cell development.  
(4) Conclusions/interpretation. Our results provide evidence for functional expression of GLP1 receptors 
in neurons known to release insulin in the cerebral cortex. Hyperglycemia increases the expression of 
GLP1 receptors in neurogliaform cells suggesting that endogenous incretins and therapeutic GLP1 
receptor agonists might have effects on these neurons similar to that of pancreatic beta cells. 
Key words:basic science, animal-rat, hormone receptors, gastro-entero pancreatic factors, other 
techniques. 
Abbreviations: BETA2, basic helix-loop-helix transcription factor; GLP1, Glucagon-like peptide 1; 
TIDMS, type I diabetes mellitus signalling; T2DM, type 2 diabetes mellitus. 
  
Research in context 
- GLP1 action on pancreatic beta cells lead to insulin secretion and current treatment of type 2 
diabetes mellitus include GLP1 receptor agonists as therapeutic agents 
- Insulin and GLP1 delivered to the brain is therapeutically promising against mild cognitive 
impairment and Alzheimer’s disease 
- Insulin is synthesized by neurons of the cerebral cortex, but it remains a question whether 
GLP1 or therapeutically applied GLP1 receptor agonists find targets on neurons capable of 
insulin production 
- We show GLP1 receptor and insulin co-expression in neurogliaform interneurons in the cerebral 
cortex 
- The expression of GLP1 receptors in neurogliaform cells is modulated by extracellular glucose 
concentrations 
- Functional expression of GLP1 receptors is supported by the reversible effect of GLP1 on 
neurogliaform cells 
- Future therapeutic strategies might include modulation of neural insulin production in the brain 
by GLP-1 agonists for counteracting diabetes, obesity and neurodegenerative diseases 
 
Introduction 
Glucagon-like peptide 1 (GLP1) produced by L-cells of the intestine is important in blood glucose 
homeostasis acting through several classic mechanisms including the inhibition of gastric emptying, 
suppressing pancreatic glucagon secretion and enhancing insulin release in the pancreas[1]. Direct 
action of circulating GLP1 on G-protein coupled GLP1 receptors located on pancreatic beta cells leads 
to glucose-dependent closure of ATP-sensitive K+ channelswith subsequent depolarization and Ca2+ 
influx and Ca2+ dependent release of Ca2+ from intra-cellular Ca2+ stores resulting in Ca2+-dependent 
insulin secretion[1].It is of high clinical importance that GLP-1 reduces the concentrations of blood 
glucose only postprandially, when blood glucose levels exceed fasting concentrations[2]. Such glucose-
dependent action renders intravenously administered GLP1 ineffective in producing hypoglycaemia and, 
consequently, current treatment of type 2 diabetes mellitus (T2DM) include GLP1 receptor agonists as 
therapeutic agents. 
Circulating GLP1 finds additional targets linked to insulin synthesis outside the pancreas. Native GLP-1 
crosses the blood brain barrier [1, 3] and thus incretins arriving from the periphery, includingGLP-
1produced by intestinal L-cells and GLP1analogues prescribed in T2DM [4], have the possibility to act 
on neurons of the hippocampus and the neocortex known to express GLP1 receptors [5, 6]. In addition, 
neurons in the brain might also receive GLP1 from central sources according to results showing GLP1 
expression in neurons located in the nucleus of the solitary tract in the brainstem[7, 8]. On the other 
hand, accumulating evidence based on experiments performed mostly in the rat shows that insulin is 
synthesized by neurons of the cerebral cortex[9–13]. Neuron-derived insulin was shown to be effective 
in regulating synaptic and microcircuit activity in the rat neocortex [13] and was suggested to regulate on 
demand energy homeostasis of neural networks[14]. 
Insulin delivered intranasally to the brain is therapeutically promising against mild cognitive impairment 
and Alzheimer’s disease [15]and the GLP1 analogues used in diabetes treatment have preventive 
effects at the early stage of AD development[16, 17] Parkinson’s disease[16, 18]and traumatic brain 
injury [19, 20]. It has been recently hypothesized that novel therapeutic strategies might include 
modulation of neural insulin production in the brain by GLP-1 agonists for counteracting diabetes, 
obesity and neurodegenerative diseases [14]. Therefore, it is of potential importance whether GLP1 of 
intestinal or neural origin or therapeutically applied GLP1 receptor agonists find targets on neurons 
capable of insulin production. We tested whether neurogliaform cells of the rat neocortex shown to 
release insulin locally the brain [13] have the molecular background to be involved in GLP1 signalling. 
 
Methods 
Electrophysiology 
All procedures were performed with the approval of the University of Szeged (no. I-74-8/2016) and in 
accordance with the Guide for the care and use of laboratory animals, Eighth edition (2011) 
(http://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf). Male wistar rats 
(n = 106, P28-35, 190-220 g, weekly supplied by Charles River) were kept in individually ventilated 
cages (0.25 m2) with biological bedding and ad libitum dry food and water. Animalswere anaesthetized 
by intraperitoneal injection of ketamine (30mg/kg) and xylazine (10mg/kg), and following the check of 
the cessation of pain reflexes and decapitation, coronal slices (350µm) were prepared from the 
somatosensory cortex. Animals used for this study also provided brain slices for other projects 
performed in parallel in the laboratory. Slice preparation and recordings were performed as described 
[13, 21]. Recordings were obtained at ~36 ˚C from cells visualized in layers I-III by infrared differential 
interference contrast videomicroscopy at depths 60-130 μm from the surface of the slice. Micropipettes 
(5-7 MΩ) were filled with an intracellular solution containing 126 mM K-gluconate, 4 mMKCl, 10 mM 
HEPES, 10 mMcreatine phosphate, 8 mMbiocytin; pH 7.25; 300 mOsm supplemented with RNase 
Inhibitor (1U/µl, Life Technologies) to prevent any RNA degradation. Slices were preincubated in 0.5 
mM glucose for 4 hours prior to hypoglycemicrecording sessions. Access resistance was monitored with 
-10 mV voltage steps in between experimental epochs and neurons were excluded from data analysis if 
access resistance exceeded 35 MΩ. Signals were filtered at 8 kHz, digitized at 16 kHz and analyzed 
with PULSE software. Traces shown are single sweeps for firing patterns. 
 
Single cell reverse transcription and digital PCR 
At the end of electrophysiological recordings, the intracellular content was aspirated into the recording 
pipettes by application of a gentle negative pressure while maintaining the tight seal [13, 21]. Pipettes 
were then delicately removed to allow outside-out patch formation, and the content of the pipettes (~ 1.5 
µl) was expelled into a low-adsorbtion test tube (Axygen) containing 0.5 µl SingleCellProtectTM (Avidin 
Ltd. Szeged, Hungary) solution in order to prevent nucleic acid degradation and to be compatible with 
direct reverse transcription reaction. Samples were snap-frozen in liquid nitrogen and stored or 
immediately used for reverse transcription. The reverse transcription of the harvested cytoplasm was 
carried out in two steps. The first step was done for 5 min at 65 °C in a total reaction volume of 5 μl 
containing 2 μl intracellular solution and SingleCellProtectTM mix with the cytoplasmic contents of the 
neuron, 0.3 μlTaqMan Assays, 0.3 μl 10 mM dNTPs, 1 μl 5X first-strand buffer, 0.3 μl 0.1 mol/L DTT, 0.3 
μl RNase inhibitor (Life Technologies) and 100 U of reverse transcriptase (Superscript III, Invitrogen). 
The second step of the reaction was carried out at 55 °C for 1 hour and then the reaction was stopped 
by heating at 75 °C for 15 min. The reverse transcription reaction mix was stored at -20 °C until PCR 
amplification. 
For digital PCR analysis, half of the reverse transcription reaction mixture (2.5 μl), 2 μlTaqMan Assays 
(Life Technologies), 10 μlOpenArray Digital PCR Master Mix (Life Technologies) and nuclease free 
water (5.5 μl) were mixed in a total volume of 20 μl. Processing of the OpenArray slide, cycling in the 
OpenArray NT cycler and data analysis were done as previously described [13, 21]. For our dPCR 
protocol amplification, reactions with CT confidence values below 100 as well as reactions having CT 
values less than 23 or greater than 33 were considered primer dimers or background signals, 
respectively, and excluded from the data set.  
 
Histology and reconstruction of neurons 
Following electrophysiological recordings, slices were immersed in a fixative containing 4% 
paraformaldehyde, 15% (v/v) saturated picric acid and 1.25% glutaraldehyde in 0.1 M phosphate buffer 
(PB; pH=7.4) at 4˚C for at least 12 h. After several washes with 0.1 M PB, slices were frozen in liquid 
nitrogen then thawed in 0.1 M PB, embedded in 10% gelatine and further sectioned into 60 µm slices. 
Sections were incubated in a solution of conjugated avidin-biotin horseradish peroxidase (ABC; 1:100; 
Vector Labs) in Tris-buffered saline (TBS, pH=7.4) at 4˚C overnight. The enzyme reaction was revealed 
by 3’3-diaminobenzidine tetra-hydrochloride (0.05%) as chromogen and 0.01% H2O2 as oxidant. 
Sections were post fixed with 1% OsO4 in 0.1 M PB. After several washes in distilled water, sections 
were stained in 1% uranyl acetate, dehydrated in ascending series of ethanol. Sections were infiltrated 
with epoxy resin (Durcupan, Sigma-Aldrich) overnight and embedded on glass slides. Three 
dimensional light microscopic reconstructions were carried out using Neurolucida system 
(MicroBrightField) with 100x objective.  
 
Statistical analysis 
Data are given as mean±S.D., datasets were statistically compared using one-way ANOVA, Kruskal-
Wallis or Wilcoxon test and Mann Whitney U-test was used for electrophysiological measurements with 
SPSS software (IBM), differences were accepted as significant if P<0.05. 
 
Results 
Morpho-physiological characteristics of identified neurogliaform cells in hyper- and hypoglycaemia 
We searched for interneurons showing characteristics of neurogliaform cells in layers 1 to 3 using the 
whole cell patch clamp mode of brain slices prepared from the somatosensory cortex of male rats (P28-
35). Acute brain slices were maintained in artificial cerebrospinal fluid (ACSF) containing glucose either 
in the concentration used as standard for in vitro brain slices (10 mM, hyperglycaemia) or a 
concentration of 0.5 mM determined as hypoglycaemic external glucose concentration in the rat brain 
[22], but still suitable for whole cell recordings from interneurons [13]. Differential interference contrast 
microscopy was used to select putative interneurons based on perisomatic morphology and the identity 
of neurogliaform cells was first confirmed according to their late spiking firing characteristics in response 
to depolarizing current pulses[13](Fig. 1a). The use of biocytin in the patch clamp recording pipettes 
allowed us to recover the morphology of the recorded cells and the identity of each neurogliaform cell 
included in this study (n = 87) was additionally confirmed by post hoc anatomical assessment of axonal 
morphology (Fig. 1a). Quantitative morphological analysis is beyond the scope of this study, however, 
the extremely dense axonal arborisation with small and frequently spaced boutons, the hallmark of 
neurogliaform cells[13]could be readily observed in samples recorded and biocytin filled in hyper- and 
hypoglycaemic conditions. In addition, no somatodendritic differences seemed to emerge between the 
two experimental groups and no morphological features considered pathological were observed.  
We compared basic electrophysiological properties of neurogliaform cells recorded in 10 mM (n = 10) 
and 0.5 mM (n = 10) external glucose concentrations (Fig. 1b). Hyper- versus hypoglycaemic conditions 
had no significant effect on the resting membrane potential (-67.08±2.66 vs.-69.52±5.28 mV, P = 0.35, 
Mann-Whitney U-test), input resistance (113.15±34.03 vs. 85.82±17.91 mΩ, P = 0.079), amplitude of 
action potentials (75.76±6.84 vs. 72.30±6.1 mV, P = 0.39), interspike interval (0.103±0.030 vs. 
0.078±0.033, ms, P = 0.094), half width of action potentials (0.82±0.27 vs. 0.56±0.12 ms, P = 0.079), 
action potential threshold (-30.89±1.77 vs. -30.9±4.8 mV, P = 0.71) and action potential accommodation 
(131.86±56.51 vs. 155.25±43.51 %, P = 0.15). However, significant differences emerged between 
neurogliaform cells recorded in 10 versus 0.5 mM glucose when measuring accommodation in the 
amplitudes of successive action potentials (90.04±6.18 vs. 81.44±6.47 %, P = 0.010) and 
accommodation in the half widths of successive action potentials (129.73±10.75 vs. 145.53±12.96 %, P 
= 0.019). Thus, apart from minor differences possibly due to the relatively lower metabolic supply in 
hypoglycaemia slightly affecting the amplitude and duration of action potentials during sustained activity, 
electrophysiological and morphological features of neurogliaform cells appear stable in our experimental 
conditions. 
 
Functional expression of GLP1 receptors and related molecular characteristics of identified 
neurogliaform cells 
Previous experiments suggest modulation of the Ins2 gene in neurogliaform cells in response to 
changes in extracellular glucose concentration [13] indicating that the function of these neurons of the 
cerebral cortex might have partially similar molecular and functional predisposition to pancreatic beta 
cells. Thus, we used the highly sensitive and quantitative method, single cell digital PCR [21], to test 
whether genes important in beta cell function and development are expressed in neurogliaform cells of 
the neocortex. In particular, GLP1 receptors promote insulin secretion on pancreatic beta cells and 
expression of these receptors on insulin releasing neurons has been suggested to have therapeutic 
implications [14]. We detected expression of GLP1 receptors in electrophysiologically and anatomically 
identified neurogliaform cells with single cell digital PCR (n = 11, Fig. 2a) using the homeostatic gene 
S18 as reference. Moreover, we comparedcopy numbers of mRNAs of the Glp1r gene in neurogliaform 
cells (n = 5) in hypoglycaemia and found that hyperglycemic copy numbers exceeded that of 
hypoglycemic copy numbers by 9.6 times when normalized to copy numbers of the homeostatic S18 
gene (0.0457 ± 0.0427 and 0.0048 ± 0.0066, P<0.008, Mann Whitney U-test, Fig. 2a).  
Next we asked whether GLP1 receptors and insulin can be co-detected in individualneurogliaform cells 
(Fig. 2b). Our single cell digital PCR method allows exact measurement of mRNA copy numbers of not 
more than two genes, thus we replaced the homeostatic gene S18 with the Ins2 gene in our protocol for 
testing GLP1 receptor and insulin co-expression. Similar to pancreatic beta cells, neurogliaform cells co-
expressed mRNAs of the Ins2 and Glp1r genes. Neurogliaform cells tested for co-expression in 
hyperglycemia (n = 5) contained higher numbers of mRNAs of both Ins2(8.60 ± 3.97) and Glp1r(8.40 ± 
4.47) genes compared to neurogliaform cells (n = 5) in hypoglycaemia (2.60 ± 1.34 and 0.80 ± 1.30; 
P<0.037 and P<0.016, respectively, Mann Whitney U-test, Fig. 2b). These results on external glucose 
concentration modulated co-expression of insulin and GLP1 receptors in neurogliaform cells confirm our 
earlier report on insulin expression[13] and its glucose modulation in neurogliaform cells and 
corroborate the results shown above for Glp1r referenced to a homeostatic gene.  
In order to confirm functional expression of GLP1 receptors, we tested the effect of GLP1 on 
electrophysiologically and anatomically identified neurogliaform cells using the hyperglycemic 
extracellular glucose concentration similar to earlier experiments [5](Fig. 2c-d). Measuring the current 
required for -90 mV holding potential in whole cell recordings before (-228 ± 39 pA, n = 11), during (-194 
± 49 pA, n = 11), and after (-214 ± 55 pA, n = 7), bath application of GLP1 (100 nM) [5], we detected a 
decrease in the holding current (P<0.003, Wilcoxon test) which was reversible upon washout (P<0.022, 
Fig. 2c-d). Moreover, pre-treatment with the GLP1 receptor specific antagonist exendin3(9-39) (1 µM) 
was effective in blocking the response in identified neurogliaform cells (n=7) to GLP1 application (-171 ± 
39 pA vs. -166 ± 32 pA, P = 0.205, Wilcoxon test, Fig. 2e). Furthermore, changes in the holding current 
in neurogliaform cells (n=6) did not occur during application of GLP1 in hypoglycemic conditions (-201 ± 
59 pA vs. -204 ± 58 pA, P = 0.401, Wilcoxon test, Fig. 2f). Accordingly, the moderate copy numbers 
relative to a homeostatic gene detected by single cell digital PCR in neurogliaform cells appear sufficient 
for a functional GLP1 response in neurogliaform interneurons. 
The co-expression of GLP1 receptors and insulin in neurogliaform cells gives rise to a potentially 
broader molecular similarity between pancreatic beta cell as and neurogliaform neurons of the cerebral 
cortex. Indeed, the developmental lineage for pancreatic endocrine cells and neurons has been 
suggestedto be related [23].Following these ideas, our final series of experiments using single cell 
digital PCR on identifiedneurogliaform cells revealed expression of transcription factors important in 
beta cell development [24, 25](Pdx1, Isl1, Mafb;copy numbers relative to S18, 0.0755 ± 0.0395, 0.0218 
± 0.0057, 0.0279 ± 0.0254, respectively Fig. 3). In addition, we detected significant increase in Pdx1 
and Isl1 mRNA copy numbersin hyperglycemia (0.0073 ± 0.0163, 0.0051 ± 0.0072;P<0.037 and 
P<0.016, respectively, Mann Whitney U-test, Fig. 3).  
 
Discussion 
Our results provide evidence for GLP1 receptor expression in neurons known to release insulin in the 
cerebral cortex. Hyperglycemia increases the expression of GLP1 receptors in neurogliaform cells 
suggesting that endogenous incretins and therapeutic GLP1 receptor agonists might have effects on 
these neurons similar to that of pancreatic beta cells. In addition, we detected transcription factors 
(Pdx1, Isl1, Mafb) in neurogliaform cells known to be important in beta cell development.  
The crucial gene in GLP1-insulin interaction, Ins2, shows significant variations when applying similar 
experimental conditions from cell type to cell type in the cerebral cortex [13], thus identification of the 
interneuron type(s) involved in the analysis is essential for appropriate interpretation of the results. Our 
combined electrophysiological, neuroanatomical and molecular techniques allowed us to monitor 
transcriptional changes associated with experimentally controlled alterations in extracellular glucose 
concentrations together with the ability to determine the identity of each neuron included in ourdataset. 
Previous analysis of transcriptional changes in identified neurons in response to variable glucose 
concentrations is scarce [13], but consistent regarding the functional effectiveness of ~10 copies of the 
Ins2 and Glp1r genes per neuron. The expression threshold for functional GLP1 receptor response 
seems to be above 2 copies of Glp1r mRNAs in low external glucose concentrations. This suggests that 
genes with moderate expression levels detected by microarray or next generation techniques [26–30] 
and potentially interesting in insulin/incretin action are worth testing in functional experiments. 
Conjoint modulation of the expression of the Ins2 and Glp1r genes reported here in identified 
neurogliaform interneurons suggest that mechanisms classically described in the pancreas for GLP1-
induced enhancement of insulin release might also operate in the brain. Application of glibenclamide 
known to promote insulin release from pancreatic beta cells has been successful in triggering insulin 
release from neurogliaform cells [13]. Although direct action of endogenous incretins or other GLP1 
receptor agonists in neuronal insulin release requires further experiments, the mode of GLP1 action and 
the polarity of responses might be cell type specific [5]. We speculate that the outward current in 
response to GLP1 in neurogliaform cells at the holding potential applied in this study support that 
activation of GLP1 receptors lead to the opening of somatic K-channels possibly linked to GABAB 
receptors and, as suggested in response to GLP1 in hypothalamic neurons [31], to increased 
presynaptic GABA release. Moreover, considering the effect of GLP1 in the enhancement of synaptic 
and tonic inhibitory currents arriving to hippocampal pyramidal cells [32]and taking into account the high 
expression of extrasynaptic GABAA receptor delta subunits found on intermediate and distal dendrites 
of neurogliaform cells [33], we cannot exclude the possibility that our results also reflect the activation 
GABAA channels located on distal dendrites and detected with poor space-clamp due to the relatively 
low input resistance of neurogliaform cells[33, 34]. Possible tonic GABAA currents induced by GLP1 on 
neurogliaform cells are in line with the involvement of neurogliaform cells shown to provide synaptic and 
extrasynaptic inhibition [33] and it is further supported by insulin triggered tonic inhibition through 
GABAA receptors [35]. It is not yet clear whether neurogliaform cells receive innervation from GLP1 
releasing neurons of the brainstem [5, 7, 8], however, in case intestinal-derived GLP1 or therapeutic 
GLP1 receptor agonists reach the cerebral cortex through the blood brain barriersimilar to native 
GLP1[3, 4] and could modulate insulin release from neurogliaform cells. The inhibition of gastric 
emptying is considered as apotentialfactor leading to weight loss caused by GLP1 receptor agonist 
therapy [2]. However, an alternative mechanism might emerge when considering imaging studies 
suggesting that the prefrontal cortex is important in the inhibitory control of food intake in humans [36–
38]and human brain slice experiments showing that neurogliaform cells provide widespread inhibition in 
prefrontal microcircuits [39]. Selective involvement of GABAergic interneuron subpopulations is likely in 
neurodegenerative diseases[40]. Given that GLP-1 receptor agonists promise therapeutic effectiveness 
against neurodegeneration in models of traumatic brain injury and Alzheimer’s and Parkinson’s 
disease[16–20], the scenario of GLP-1 receptor mediated insulin synthesis in the brain could be 
extended to the therapy of these diseases. 
A related developmental lineage for pancreatic endocrine cells and neurons has been implicated [23] 
and our results on the limited number of transcription factors tested in neurogliaform cells here support 
this idea. The pancreatic duodenal homeobox gene-1 (Pdx1) is central in the regulation of pancreatic 
development and in the differentiation of beta cells from progenitor cells[24]. The effects of GLP1 on 
beta cell proliferation and its secretory function depends on cross talk with proteins in the insulin 
signalling pathway and by modulation of transcription factors including PDX1[24], thus the co-
expression of Glp1r, Pdx1 and the TIDMS pathway found in neurogliaform cells suggest potential 
functional homology of neurogliaform and beta cells beyond development. Along the same vein, 
expression of the LIM homeodomain protein ISL1 (insulin gene enhancer binding protein, islet factor 1) 
is known from the developing pancreas and the central nervous system [41, 42]. Synergistically with the 
basic helix-loop-helix transcription factor BETA2, ISL1 activates the insulin promoter in beta cells [43], 
promotes pancreatic islet cell proliferation [44] and ISL1 is required for the differentiation of interneurons 
in the spinal chord[45]. The role of musculoaponeuroticfibrosarcoma oncogene family A and B (Mafa 
and Mafb) genes is crucial in beta cells during development (Mafb) and adulthood (Mafa in mouse and 
MAFA and MAFB in human) [46] and our results in neurogliaform cells confirm the widespread 
expression of MAFB reported earlier in developing and differentiated neocortical interneurons [47]. Our 
results suggest that insulin and GLP1R expressing neurogliaform interneurons of the cerebral cortex 
partially possess the transcription toolkit known to be instrumental in the development of insulin 
synthesizing pancreatic beta cells. 
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Fig. 1 
Anatomical and electrophysiological features of neurogliaform cells harvested for transcriptomic 
analysis. (a) Three dimensional reconstructions and firing patterns of neurogliaform cells whole cell 
patch clamp recorded and subsequently harvested for molecular analysis in brain slices of rat frontal 
cortex. The neurogliaform cell on the left (soma, dendrites and somatically recorded firing pattern, red; 
axon, orange) was recorded having hyperglycemic external glucose concentration (10 mM) in the 
artificial cerebrospinal fluid, which is standard in brain slice experiments. The neurogliaform cell on the 
right (soma, dendrites and somatically recorded firing pattern, blue; axon, light blue) was recorded in 
artificial cerebrospinal fluid containing 0.5 mM glucose reported during hypoglycaemia in the brain [22]. 
(b) Electrophysiological parameters of neurogliaform cell measured in hyperglicemia (red) and 
hypoglicemia (blue). Basic membrane parameters were not significantly different, however, the 
amplitude of action potentials (Aps) during a train decreased at a significantly higher rate in 
neurogliaform cells recorded in hypoglycaemia and the half width of their successive action potentials 
increased more rapidly compared to neurogliaform cell measured in hyperglycemia. 
 
Fig. 2 
Functional expression of GLP1 receptors in neurogliaform cells. (a) Expression of GLP1 receptors in 
electrophysiologically and anatomically identified neurogliaform cells detected by single cell digital PCR. 
Copy numbers of Glp1r mRNAs were higher in hyperglycemiacompared to hypoglycaemia when 
normalized to copy numbers of the homeostatic S18 gene. (b) Co-expression of GLP1 receptors and 
insulin in individual neurogliaform cells. Neurogliaform cells tested for co-expression in hyperglycemia 
contained higher numbers of mRNAs of both Ins2 and Glp1r genes compared to neurogliaformcells in 
hypoglycaemia. (c-f) Functional expression of GLP1 on neurogliaform cells.(c) Example of an 
experiment testing the effect of GLP1 (100 nM) on identified neurogliaform cells. Left, Firing pattern of a 
neurogliaform cell recorded having hyperglycemic external glucose concentration (10 mM) in the 
artificial cerebrospinal fluid. Right, Application of 100 nM GLP1 to the neurogliaform cell (same as on 
left) alters the current required for -90 mV holding potential. (d) Population data confirm a decrease in 
the holding current which was reversible upon washout. Four out of 11 experiments were terminated 
before washout due to unstable access resistance.(e) Pre-treatment with the GLP1 receptor specific 
antagonist exendin3(9-39) (1 µM) blocked the response in identified neurogliaform cells to GLP1 
application.(f) Changes in the holding current in neurogliaform cells did not occur during application of 
GLP1 in hypoglycaemia. 
 Fig. 3 
Single cell digital PCR of neurogliaform cells confirms expression of transcription factors important in 
beta cells. Changes in extracellular glucose concentrations modulate the copy number of Isl1 and Pdx 
mRNAs in electrophysiologically and anatomically identified neurogliaform cells.  
 
